Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: Effect of an antioxidant treatment

被引:51
作者
Loffredo, Lorenzo
Pignatelli, Pasquale
Cangemi, Roberto
Andreozzi, Paola
Panico, Maria Antonietta
Meloni, Valerio
Violi, Francesco
机构
[1] Univ Roma La Sapienza, Div Clin Med 4, Dept Expt Med & Pathol, I-00161 Rome, Italy
[2] Univ Roma La Sapienza, Dipartimento Chirurg Vasc Paride Stefanini, I-00161 Rome, Italy
[3] Univ Roma La Sapienza, Dipartimento Sci Chirurg & Tecnol Applicate F Dur, I-00161 Rome, Italy
关键词
PROPIONYL-L-CARNITINE; OCCLUSIVE DISEASE; VASCULAR-DISEASE; IMPROVES; PHARMACOKINETICS; ATHEROSCLEROSIS; AUTOANTIBODIES; CLAUDICATION; EXERCISE; FLOW;
D O I
10.1016/j.jvs.2006.05.023
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Nitric oxide (NO), a potent vasodilator produced by endothelial cells, is reduced in patients with peripheral arterial disease (PAD), but the mechanism has not been fully elucidated. Because NO is rapidly inactivated by superoxide anion, we speculated that enhanced oxidative stress could lower NO generation. The aim of our study was to investigate if an imbalance between oxidative stress and NO does exist in patients with PAD and if an increase of NO formation could be achieved by an antioxidant treatment. Methods: In a first study, serum levels of nitrite and nitrate (NOx), markers of NO generation, and 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative stress and maximal walking distance (MWD), were measured in 40 PAD patients and 40 controls. In a second study, 10 PAD patients were randomly allocated in a crossover design to intravenous propionyl-L-carnitine (6 g/day) or placebo for 7 days, with a washout of 30 days between the two phases of the trial. Serum levels of NOx and 8-OHdG were measured before and after the study. Results: Compared with controls, serum levels of 8-OHdG (mean +/- SD) were significantly increased in PAD patients (4.4 +/- 3.1 ng/mL vs 2.4 +/- 1.2 ng/mL; P < .001), and serum levels of NOx were significantly decreased (11.6 +/- 6 mu M vs 17 +/- 6.1 WM; P < .001). Levels of 8-OHdG and NOx were inversely correlated (r = -0.879; P <.001). Serum levels 8-OHdG were inversely correlated with MWD (r = -0.48, P =.002). The interventional trial showed no changes in the patients given placebo. Patients treated with propionyl-L-carnitine showed a significant increase of MWD from 101 +/- 31 meters to 129 +/- 35 meters (P = .007) and in NOx from 14.5 +/- 4.5 mu M to 17.1 +/- 3.8 mu M (P =.007). A significant decrease of 8-OHdG from 3.6 +/- 1.1 ng/mL to 2.6 +/- 1 ng/mL was also found (P =.005.) Conclusions: This study suggests that in PAD patients, the reduction of NO generation could be dependent upon enhanced oxidative stress.
引用
收藏
页码:525 / 530
页数:6
相关论文
共 22 条
[1]   Nitric oxide and arterial disease [J].
Barbato, JE ;
Tzeng, E .
JOURNAL OF VASCULAR SURGERY, 2004, 40 (01) :187-193
[2]   PATIENTS WITH EARLY-ONSET PERIPHERAL VASCULAR-DISEASE HAVE INCREASED LEVELS OF AUTOANTIBODIES AGAINST OXIDIZED LDL [J].
BERGMARK, C ;
WU, R ;
DEFAIRE, U ;
LEFVERT, AK ;
SWEDENBORG, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (04) :441-445
[3]   Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease [J].
Boger, RH ;
BodeBoger, SM ;
Thiele, W ;
Junker, W ;
Alexander, K ;
Frolich, JC .
CIRCULATION, 1997, 95 (08) :2068-2074
[4]   Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease [J].
Böger, RH ;
Bode-Böger, SM ;
Thiele, W ;
Creutzig, A ;
Alexander, K ;
Fröhlich, JC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (05) :1336-1344
[5]   Flow, NO, and atherogenesis [J].
Cooke, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (03) :768-770
[6]  
Criqui M H, 1998, Vasc Med, V3, P241, DOI 10.1177/1358836X9800300311
[7]  
DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50
[8]   PHARMACOKINETICS OF BOLUS INTRAVENOUS AND ORAL DOSES OF L-CARNITINE IN HEALTHY-SUBJECTS [J].
HARPER, P ;
ELWIN, CE ;
CEDERBLAD, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (01) :69-75
[9]   L-citruiline and L-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits [J].
Hayashi, T ;
Juliet, PAR ;
Matsui-Hirai, H ;
Miyazaki, A ;
Fukatsu, A ;
Funami, J ;
Iguchi, A ;
Ignarro, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (38) :13681-13686
[10]   Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication [J].
Hiatt, WR ;
Regensteiner, JG ;
Creager, MA ;
Hirsch, AT ;
Cooke, JP ;
Olin, JW ;
Gorbunov, GN ;
Isner, J ;
Lukjanov, YV ;
Tsitsiashvili, MS ;
Zabelskaya, TF ;
Amato, A .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (08) :616-622